[1]Fan L,Strasser-Weippl K,Li JJ,et al.Breast cancer in China［J］.Lancet Oncol,2014,15(7):e279-e289.
[2]Desantis C,Ma J,Bryan L,et al.Breast cancer statistics,2013［J］.CA Cancer J Clin,2014,64(1):52-62.
[3]Charles Perou TS,Michael Eisen.Molecular portraits of hunman breast tumours［J］.Nature,2000,406:747-752.
[4]Wang CY.Astrocyte elevated gene-1 and breast cancer（review)［J］.Oncol Lett,2011,2(3):399-405.
[5]Elizabeth H，Hammond DFH,Mitch Dowsett.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer（Unabridged Version)［J］.Arch Pathol Lab Med,2010,134:e48-e74.
[6]Wolff AC,Hammond ME,Hicks DG,et al.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update［J］.J Clin Oncol,2013,31(31):3997-4013.
[7]Dowsett M,Nielsen TO,A'hern R,et al.Assessment of Ki67 in breast cancer:Recommendations from the international Ki67 in Breast Cancer Working Group［J］.J Natl Cancer Inst,2011,103(22):1656-1664.
[8]A Goldhirsch EPW,AS Coates.Personalizing the treatment of women with early breast cancer:Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013［J］.Annals of Oncol,2013，24:2206-2223.
[9]Su P,Zhang Q,Yang Q.Immunohistochemical analysis of Metadherin in proliferative and cancerous breast tissue［J］.Diagn Pathol,2010,5:38-41.
[10]Parker JS,Mullins M,Cheang MC,et al.Supervised risk predictor of breast cancer based on intrinsic subtypes［J］.J Clin Oncol,2009,27(8):1160-1167.
[11]A Goldhirsch EPW,Wood WC,AS Coates,et al.Strategies for subtypes-dealing with the diversity of breast cancer:Highlights of the St.Gallen International Expert Consensus on the primary therapy of early breast cancer 2011［J］.Ann Oncol,2011,22(8):1736-1747.
[12]Shim HJ,Kim SH,Kang BJ,et al.Breast cancer recurrence according to molecular subtype［J］.Asian Pacific J Cancer Prevention,2014,15(14):5539-5544.
[13]Dawood S,Hu R,Homes MD,et al.Defining breast cancer prognosis based on molecular phenotypes:Results from a large cohort study［J］.Breast Cancer Res Treat,2011,126(1):185-192.
[14]Gluck S,De Snoo F,Peeters J,et al.Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy［J］.Breast Cancer Res Treat,2013,139(3):759-767.
[15]Cancello G,Maisonneuve P,Rotmensz N,et al.Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse［J］.Ann Oncol,2013,24(3):661-668.
[16]Yang Q，Chen H,Li HJ.Clinical features and prognosis analysis of different breast cancer molecuar subtypes［J］.Chin J Oncol,2010,33:42-49.［杨钱，陈浩，李宏江.不同分子亚型乳腺癌的临床病理特征及预后分析［J］.中华肿瘤杂志,2010,33:42-49.］
[17]Joosse SA,Brandwijk KI,Mulder L,et al.Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors［J］.Genes Chromosomes Cancer,2011,50(2):71-81.
[18]Liu M,Mo QG,Wei CY,et al.Platinum-based chemotherapy in triple-negative breast cancer:A Meta-analysis［J］.Oncol Lett,2013,5(3):983-991.
[19]Zaozhong Su,Yinming Chen.Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization,RaSH［J］.Oncogene,2002,21:3592-3602.
[20]Tokunaga E,Nakashima Y,Yamashita N,et al.Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer［J］.Breast Cancer,2014,21(3):341-349.
[21]Li C,Li R,Song H,et al.Significance of AEG-1 expression in correlation with VEGF,microvessel density and clinicopathological characteristics in triple-negative breast cancer［J］.J Surg Oncol,2011,103(2):184-192.
[22]Jin P,Xie XD,Liu ZZ,et al.Expression of metadherin gene in metastatic breast cancer and its clinical significance［J］.Acad J Chin PLA Med School,2013,34（2）:133-136.［靳鹏，谢晓冬，刘兆喆，等.异黏蛋白在复发转移性乳腺癌表达及其临床意义的研究［J］.解放军医学院学报,2013,34（2）:133-136.］
[23]You Zhenyu,Liu Yang.MTDH expression in triple negative breast cancer and its association with first line chemptherapy［J］.Modern Oncology,2014,22（6）:1315-1318.［尤振宇，刘洋.MTDH在三阴性乳腺癌中的表达及与一线化疗的关系［J］.现代肿瘤医学,2014,22（6）:1315-1318.］
[24]Zhang N,Wang X,Huo Q,et al.The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL（Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer［J］.J Biol Chem,2013,288(13):9396-9407.
[25]Xu C,Kong X,Wang H,et al.MTDH mediates estrogen-independent growth and tamoxifen resistance by down-regulating PTEN in MCF-7 breast cancer cells［J］.Cell Physiol Biochem,2014,33(5):1557-1567.
[26]Li X,Kong X,Huo Q,et al.Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition［J］.Cancer Sci,2011,102(6):1151-1157.
[27]Meng X,Brachova P,Yang S,et al.Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment［J］.PLoS One,2011,6(6):e20920.
[28]Kong X,Moran MS,Zhao Y,et al.Inhibition of metadherin sensitizes breast cancer cells to AZD6244［J］.Cancer Biol Ther,2012,13(1):43-49.
[29]Liu Y,Kong X,Li X,et al.Knockdown of metadherin inhibits angiogenesis in breast cancer［J］.Int J Oncol,2015,46(6):2459-2466.
[30]Wenjing Zhou,Rose-Marie Amini.Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis:A population-based cohort study［J］.BMC Cancer,2013,13:512-514.
[31]Engels CC,Fontein DB,Kuppen PJ,et al.Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma［J］.Br J Cancer,2014,111(3):532-538.
[32]Lim SK,Lee MH,Park IH,et al.Impact of molecular subtype conversion of breast cancers after neoadjuvant chemotherapy on clinical outcome［J］.Cancer Res Treat,2015,7:e1-e9.